UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2331-2
Program Prior Authorization/Medical Necessity
Medication Xphozah® (tenapanor)
P&T Approval Date 1/2025
Effective Date 4/1/2025
1. Background:
Xphozah® (tenapanor) is a sodium hydrogen exchanger 3 (NHE3) inhibitor indicated to reduce
serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in
patients who have an inadequate response to phosphate binders or who are intolerant of any dose
of phosphate binder therapy.
2. Coverage Criteriaa:
A. Initial Authorization
1. Xphozah will be approved based upon all of the following criteria:
a. Diagnosis of chronic kidney disease (CKD)
-AND-
b. Patient is receiving dialysis
-AND-
c. Serum phosphorus is > 6.5 mg/dL
-AND-
d. Patient has had an inadequate response to a maximally tolerated dose of two of the
following phosphate binders:
(1) calcium acetate (generic PhosLo)
(2) lanthanum carbonate (generic Fosenrol)
(3) sevelamer carbonate (generic Renvela)
(4) Velphoro (sucroferric oxyhydroxide)]
-AND-
e. Xphozah will be used as add-on therapy
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
f. Prescribed by or in consultation with a nephrologist.
Authorization will be issued for 12 months.
B. Reauthorization
1. Xphozah will be approved based on both the following criterion:
a. Documentation of positive clinical response to Xphozah therapy [e.g., reduction of serum
phosphorus towards the normal range (3.5 to 5.5 mg/dL)]
-AND-
b. Prescribed by or in consultation with a nephrologist.
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. Reference:
1. Xphozah® [package insert]. Waltham, MA: Ardelyx, Inc.; October 2023
2. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and
disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO
clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic
Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-
S130. doi:10.1038/ki.2009.188
4. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic
Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and
why it matters [published correction appears in Kidney Int. 2017 Dec;92(6):1558]. Kidney Int.
2017;92(1):26-36. doi:10.1016/j.kint.2017.04.006
Program Prior Authorization/Medical Necessity - Xphozah (tenapanor)
Change Control
3/2024 New program.
1/2025 Annual review with no updates.
© 2025 UnitedHealthcare Services, Inc.
2